Quick Answer
ADC Therapeutics SA reported Cash and Equivalents of $261.34 million for fiscal year 2025.
ADC Therapeutics SA Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $261.34M | +4.2% |
| 2024 | $250.87M | -10.0% |
| 2023 | $278.60M | -14.7% |
| 2022 | $326.44M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $234.74M | -14.4% | -11.3% |
| June 30, 2025 | $264.56M | -11.8% | +35.9% |
| March 31, 2025 | $194.70M | -16.9% | -22.4% |
| December 31, 2024 | $250.87M | -10.0% | -8.5% |
| September 30, 2024 | $274.27M | — | -8.6% |
| June 30, 2024 | $300.12M | — | +28.1% |
| March 31, 2024 | $234.28M | — | -15.9% |
| December 31, 2023 | $278.60M | — | — |
- ADC Therapeutics SA showed an increase of +4.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s cash and equivalents has declined by 19.9% (from $326.44 million to $261.34 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: